- Report
- July 2023
- 102 Pages
Global
From €3500EUR$3,934USD£3,107GBP
- Report
- January 2024
- 109 Pages
Global
From €3500EUR$3,934USD£3,107GBP
- Report
- October 2023
- 146 Pages
Global
From €3362EUR$3,528USD£2,884GBP
€3955EUR$4,150USD£3,393GBP
- Report
- July 2022
- 57 Pages
Global
From €3336EUR$3,500USD£2,862GBP
- Report
- May 2022
- 122 Pages
Global
From €1906EUR$2,000USD£1,635GBP
- Report
- May 2022
- 75 Pages
Global
From €1906EUR$2,000USD£1,635GBP
- Report
- February 2022
- 80 Pages
Africa
From €3617EUR$3,795USD£3,103GBP
- Report
- February 2022
- 40 Pages
Brazil
From €2473EUR$2,595USD£2,122GBP
- Report
- February 2022
- 40 Pages
China
From €2473EUR$2,595USD£2,122GBP
- Report
- February 2022
- 40 Pages
France
From €2473EUR$2,595USD£2,122GBP
- Report
- February 2022
- 40 Pages
Germany
From €2473EUR$2,595USD£2,122GBP
- Report
- February 2022
- 40 Pages
Ireland
From €2473EUR$2,595USD£2,122GBP
- Report
- February 2022
- 40 Pages
Japan
From €2473EUR$2,595USD£2,122GBP
- Report
- February 2022
- 40 Pages
Russia
From €2473EUR$2,595USD£2,122GBP
- Report
- February 2022
- 40 Pages
South Korea
From €2473EUR$2,595USD£2,122GBP
- Report
- February 2022
- 40 Pages
United States
From €2473EUR$2,595USD£2,122GBP
- Report
- February 2022
- 40 Pages
Vietnam
From €2473EUR$2,595USD£2,122GBP
- Report
- November 2021
- 600 Pages
Global
From €3812EUR$4,000USD£3,270GBP
- Report
- December 2023
- 279 Pages
Global
From €3517EUR$3,690USD£3,017GBP
- Report
- March 2023
- 374 Pages
Global
From €3403EUR$3,570USD£2,919GBP
Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more